Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Cadila Healthcare Ltd    CADILAHC   INE010B01027

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Cadila Healthcare : gets Mexico regulator approval for Lipaglyn

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:58pm CET

Cadila Healthcare Ltd is currently trading at Rs 465, down by Rs 13.65 or 2.85% from its previous closing of Rs 478.65 on the BSE. Zydus today announced that the Mexico regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval to commercialize Lipagly (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.

Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyceridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH). Increased triglyceride accumulation in the liver can also lead to inflammation, fibrosis, cirrhosis and liver failure, a serious medical condition known as NAFLD or NASH. Additionally, Zydus is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).

"Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia", said Pankaj Patel, Chairman, Zydus Group, and added, "This approval of Saroglitazar in Mexico is a major milestone for the company."

Cadila Healthcare Ltd is currently trading at Rs 465, down by Rs 13.65 or 2.85% from its previous closing of Rs 478.65 on the BSE. The scrip opened at Rs 476 and has touched a high and low of Rs 478 and Rs 464.5 respectively.

(c) 2017India Infoline Ltd. All rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CADILA HEALTHCARE LTD
11/20 CADILA HEALTHCARE : Zydus receives final approval from the USFDA for Ethacrynate..
11/16 CADILA HEALTHCARE : Pharma growth to pick up in 2nd half
11/15 CADILA HEALTHCARE : Q2 profit up 32% at Rs 503 crore
11/15 CADILA HEALTHCARE : Q2 NET PROFIT UP 32% AT Rs503 CRORE
11/13 CADILA HEALTHCARE : Mexico okays cadila drug
11/10 CADILA HEALTHCARE : gets Mexico regulator approval for Lipaglyn
11/03 CADILA HEALTHCARE : up 2% after arm gets USFDA nod
11/03 CADILA HEALTHCARE : Nesher Pharma gets USFDA nod to market ADHD tablets
11/03 CADILA HEALTHCARE : up 2% after arm gets USFDA nod
11/03 CADILA HEALTHCARE : Zydus arm gets us nod for drug
More news
Financials ( INR)
Sales 2018 116 B
EBIT 2018 23 273 M
Net income 2018 19 217 M
Debt 2018 26 511 M
Yield 2018 0,88%
P/E ratio 2018 23,63
P/E ratio 2019 19,05
EV / Sales 2018 4,15x
EV / Sales 2019 3,58x
Capitalization 456 B
Chart CADILA HEALTHCARE LTD
Duration : Period :
Cadila Healthcare Ltd Technical Analysis Chart | CADILAHC | INE010B01027 | 4-Traders
Technical analysis trends CADILA HEALTHCARE LTD
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 38
Average target price 506  INR
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Sharvil Pankajbhai Patel Joint Managing Director & Executive Director
Pankaj Ramanbhai Patel Executive Chairman & Joint Managing Director
Ganesh Narayan Nayak Chief Operating Officer & Executive Director
Nitin Dalsukhrai Parekh Chief Financial Officer
Humayun Raja Dhanrajgir Independent Non-Executive Director
Sector and Competitors